Virtanen R, Iisalo E, Parvinen M, Nordman E
Acta Pharmacol Toxicol (Copenh). 1979 Apr;44(4):296-302. doi: 10.1111/j.1600-0773.1979.tb02333.x.
A sensitive (sensitivity 2.2 X 10(-9) mol/l) and specific (practically no cross-reaction with circulating folates) radioimmunoassay for the determination of methotrexate concentrations in biological fluids in described and compared with a commercial competitive protein binding assay. Antiserum with high titer was produced in rabbits immunized with MTX-human serum albumin conjugate. Fitness for use in pharmacokinetic drug level determinations was shown in three patients, who received both low doses and high dose therapy combined with citrovorum factor rescue. An excellent correlation was found between plasma and urine MTX concentrations obtained by RIA and competitive protein binding assay. A two-compartment pharmacokinetic model was found adequately describing the serum decay curves, but there was a great interindividual variability in the calculated pharmacokinetic parameters.
本文描述了一种用于测定生物体液中甲氨蝶呤浓度的灵敏(灵敏度为2.2×10⁻⁹mol/L)且特异(与循环叶酸几乎无交叉反应)的放射免疫分析法,并与一种商业竞争性蛋白结合分析法进行了比较。用甲氨蝶呤-人血清白蛋白偶联物免疫兔子制备了高滴度抗血清。在三名接受低剂量和高剂量治疗并联合亚叶酸解救的患者中,证明了该方法适用于药代动力学药物水平测定。通过放射免疫分析法和竞争性蛋白结合分析法获得的血浆和尿液中甲氨蝶呤浓度之间发现了极好的相关性。发现二室药代动力学模型能充分描述血清衰减曲线,但计算得到的药代动力学参数存在很大的个体间差异。